Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Justin M. Watts(Sylvester Comprehensive Cancer Center), Jörge E. Cortes(Augusta University Health), Andrew H. Wei(The Royal Melbourne Hospital), P. Brent Ferrell(Vanderbilt University Medical Center), Stéphane de Botton(Université Paris-Saclay), Montserrat Arnán Sangerman(Institut Català d'Oncologia), Jay Yang(Boston Children's Hospital), William B. Donnellan(Sarah Cannon), Hesham Mohamed(Bristol-Myers Squibb (United States)), Thomas Prébet(Yale University), Gary J. Schiller(Fred Hutch Cancer Center), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Sylvie M. Guichard(Novo Nordisk (United Kingdom)), Sanjeev Forsyth(Forma Therapeutics (United States)), Maria R. Baer(University of Maryland, Baltimore), Shira Dinner(Dana-Farber Cancer Institute), Patrick Kelly(University of Wisconsin–Madison), Brian A. Jonas(Cellular Therapeutics (United Kingdom)), Julie Brevard(Idera Pharmaceuticals (United States)), Patrick Henrick(Forma Therapeutics (United States)), Karen Seiter(New York Medical College), Sang‐Min Lee(Seoul National University), Kim‐Hien Dao(Oregon Health & Science University), Arnaud Pigneux(Centre Hospitalier Universitaire de Bordeaux), Jennifer Sweeney(University of Michigan), Pau Montesinos(Instituto de Salud Carlos III)
Blood
November 13, 2019
Cited by 26


Related Papers